Lyra Therapeutics(US:LYRA)2025-11-12 21:04Financial Performance - Cash and cash equivalents as of September 30, 2025, were $22.1 million, down from $40.6 million at December 31, 2024[4]. - Net loss for Q3 2025 was $6.0 million, an improvement from a net loss of $11.9 million in Q3 2024[9]. - Collaboration revenue for Q3 2025 was $25, down from $195 in Q3 2024[10]. - Total operating expenses for Q3 2025 were $6.3 million, compared to $12.6 million in Q3 2024[10]. - The restructuring credit for Q3 2025 was $21, compared to a charge of $2.8 million in Q3 2024[9]. Expenses - Research and development expenses decreased by $1.9 million to $4.0 million for Q3 2025 compared to $5.9 million in Q3 2024[5]. - General and administrative expenses decreased by $1.7 million to $2.2 million for Q3 2025 compared to $3.9 million in Q3 2024[7]. Future Plans - The company plans a new Phase 3 clinical trial for LYR-210 to support NDA submission for CRS treatment[2]. - LYR-210 is designed to deliver six months of continuous anti-inflammatory therapy for CRS patients[13]. - The company anticipates its cash balance will fund operations into Q3 2026[4].